# MK-0646, Etoposide, and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer

> **NCT00869752** · PHASE1,PHASE2 · COMPLETED · sponsor: **NCIC Clinical Trials Group** · enrollment: 12 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **BIOLOGICAL:** anti-IGF-1R recombinant monoclonal antibody MK-0646
- **DRUG:** cisplatin
- **DRUG:** etoposide

## Key facts

- **NCT ID:** NCT00869752
- **Lead sponsor:** NCIC Clinical Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12-16
- **Primary completion:** 2012-03-15
- **Final completion:** 2012-07-04
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2023-08-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00869752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00869752, "MK-0646, Etoposide, and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00869752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*